Role of the neutrophil in myocardial ischemiareperfusion injury

Journal of Organ Dysfunction

Volumn 5, Issue 4, 2009, Pages 193-207

  Pasnik, Jarek ^a   Zeman, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Anti neutrophil therapy; Cardiopulmonary bypass; Ischemiareperfusion heart injury; Neutrophil

Indexed keywords

APROTININ; CD31 ANTIGEN; CYTOKINE; ENZYME INHIBITOR; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 6; L SELECTIN; LEUKOCYTE ELASTASE; PENTOXIFYLLINE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

CELL ADHESION; CELL FUNCTION; CLINICAL FEATURE; DRUG MECHANISM; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HEART MUSCLE ISCHEMIA; HEART SURGERY; HUMAN; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; RESPIRATORY BURST; REVIEW;

EID: 70450257805     PISSN: 17471060     EISSN: 17471079     Source Type: Journal    
DOI: 10.3109/17471060802227122     Document Type: Review

References (85)

1. Carden DL, Granger DN. Pathophysiology of ischaemiareperfusion injury. J Pathol 2000;/190:/255-66.
2. Zhao ZQ, Nakamura M, Wang NP, Wilcox JN, Shearer S, Ronson RS, et al. Reperfusion induces myocardial apoptotic cell death. Cardiovasc Res 2000;/43:/651-60.
3. Chatelain P, Latour JG, Tran D, de Lorgeril M, Dupras G, Bourassa M. Neutrophil accumulation in experimental myocardial infarcts: relation with extent of injury and effect of reperfusion. Circulation 1987;/75:/1083-90.
4. de Lorgeril M, Rousseau G, Basmadjian A, St-Jean G, Tran DC, Latour JG. Spacial [sic.] and temporal profiles of neutrophil accumulation in the reperfused ischemic myocardium. Am J Cardiovasc Pathol 1990;/3:/143-54.
5. Williams FM. Neutrophils and myocardial reperfusion injury. Pharmacol Ther 1996;/72:/1-12.
6. Bohle RM, Klein HH, Pich S, Lindert-Heimberg S, Gehrke D, Nebendahl K. Interstitial myocardial neutrophil accumulation between 3 and 72 h of reperfusion does not significantly affect infarct size in porcine hearts. Am J Cardiovasc Pathol 1993;/4:/336-42.
7. Braunwald E, Kloner RA. Myocardial reperfusion: a doubleedged sword? J Clin Invest 1985;/76:/17113-9.
8. Ebderhardt F, Melholm U, Larose K, De Vivie ER, Dhein S. Structural myocardial changes after coronary artery surgery. Eur J Clin Invest 2000;/30:/938-46.
9. Baxter GF. The neutrophil as a mediator of myocardial ischemia-reperfusion injury: time to move on. Basic Res Cardiol 2002;/97:/268-75.
10. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part I. Circulation 2001;/104:/2981-9.
11. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part II. Circulation 2001;/104:/3158-67.
12. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 1999;/6:/1905-12.
13. Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 1983;/ 67:/1016-23.
14. Jeroudi MO, Hartley CJ, Bolli R. Myocardial reperfusion injury: role of oxygen radicals and potential therapy with antioxidants. Am J Cardiol 1994;/73:/2B-7B. (Pubitemid 24093495)
15. Pernov J, Gonon AT, Gourine A. The role of the endothelium for reperfusion injury. Eur Heart J 2001;/3:/C22-7.
16. Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 2006;/70:/ 181-90.
17. Lucchesi BR. Complement, neutrophil and free radicals: mediators of reperfusion injury. Arzneimittelforschung 1994;/ 44:/420-32.
18. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004;/61:/481-97.
19. Chakraborti T, Mandal A, Mandal M, Das S, Chakraborti S. Complement activation in heart diseases. Role of oxidants. Cell Signal 2000;/12:/607-17.
20. Tarnok A, Hambsch J, Emmrich F, Sack U, Son J, Bellinghausen W, et al. Complement activation, cytokines, and adhesion molecules in children undergoing cardiac surgery with or without cardiopulmonary bypass. Pediatr Cardiol 1999;/20:/113-25.
21. Kotani T, Kotake Y, Morisaki H, Takeda J, Shimizu H, Ueda T, et al. Activation of a neutrophil-derived inflammatory response in the airways during cardiopulmonary bypass. Anesth Analg 2006;/103:/1394-9.
22. de Oliveira-Marques V, Cyrne L, Marinho HS, Antunes F. A quantitative study of NF-kappa B activation by H2O2: relevance in inflammation and synergy with TNF-alpha. J Immunol 2007;/178:/3893-902.
23. Sawa Y, Ichikawa H, Kagisaki K, Ohata T, Matsuda H. Interleukin-6 derived from hypoxic myocytes promotes neutrophil- mediated reperfusion injury in myocardium. J Thorac Cardiovasc Surg 1998;/116:/511-7.
24. Zhao Y, Wang LM, Chaiswing L, Yen HC, Oberley TD, Lien YC, et al. Tamoxifen protects against acute tumor necrosis factor alpha-induced cardiac injury via improving mitochondrial functions. Free Radic Biol Med 2006;/40:/1234-41.
25. Penicka M, Gregor P, Krupicka J, Jira M. Tumour necrosis factor-alpha soluble receptors type I are related to symptoms and left ventricular function in hypertrophic cardiomyopathy. Can J Cardiol 2001;/17:/777-84.
26. Dorge H, Schulz R, Belosjorow S, Post H, van de Sand A, Konietzka I, et al. Coronary microembolization: the role of TNF-a in contractile dysfunction. J Moll Cell Cardiol 2002;/ 34:/51-62.
27. Sbrana S, Bevilacqua S, Buffa M, Spiller D, Parri MS, Gianetti J, et al. Post-reperfusion changes of monocyte function in coronary blood after extracorporeal circulation. Cytometry B Clin Cytom 2005;/65:/14-21.
28. Auchampach JA, Pieper GM, Cavero I, Gross GJ. Effect of the platelet-activating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function. Basic Res Cardiol 1998;/93:/361-71.
29. Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Haemost 2007;/97:/738-47.
30. Jensen RH, Stoorgaard M, Vedelsdal R, Obel N. Impaired neutrophil chemotaxis after cardiac surgery. Scand J Thorac Cardiovasc Surg 1995;/29:/115-8.
31. Brix-Christensen V, Petersen TK, Ravn HB, Hjordtal VE, Andersen NT, Tonnesen E. Cardiopulmonary bypass elicits a pro- and anti-inflammatory cytokine response and impaired neutrophil chemotaxis in neonatal pigs. Acta Anaesthesiol Scand 2001;/45:/407-13.
32. Gessler P, Pretre R, Hohl V, Rousson V, Fischer J, Dahinden C. CXC-chemokine stimulation of neutrophils correlates with plasma levels of myeloperoxidase and lactoferrin and contributes to clinical outcome after pediatric cardiac surgery. Shock 2004;/22:/513-20.
33. Mazzone A, Ricevuti G. Leukocyte CD11/CD18 integrins: biological and clinical relevance. Haematologica 1995;/80:/ 161-75.
34. Harlan JM, Winn RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med 2002;30(Suppl):s214-9.
35. Hogg N, Bates PA, Harvey J. Structure and function of intercellular adhesion molecule-1. Chem Immunol 1991;/50:/ 98-115.
36. Lefer AM. Role of selectins in myocardial ischemia-reperfusion injury. Ann Thorac Surg 1995;/60:/773-7.
37. Elliott MJ, Finn AHR. Interaction between neutrophils and the endothelium. Ann Thorac Surg 1993;/56:/1503-8.
38. Chen YF, Tsai WC, Lin CC, Tsai LY, Lee CS, Huang CH, et al. Effect of leukocyte depletion on endothelial cell activation and transendothelial migration of leukocytes during cardiopulmonary bypass. Ann Thorac Surg 2004;/78:/634-42.
39. Lefer AM. Role of the beta-2-integrins and immunoglobulin superfamily members in myocardial ischemia-reperfusion. Ann Thorac Surg 1999;/68:/1920-3.
40. Schulze CJ, Wang W, Suarez-Pinzon WL, Sawicka J, Sawicki G, Schulz R. Imbalance between tissue inhibitor of metalloproteinase- 4 and matrix metalloproteinases during acute myocardial ischemia-reperfusion injury. Circulation 2003;/ 107:/2487-92.
41. Eberl T, Amberger A, Herold M, Hengster P, Steurer W, Hochleitner BW, et al. Expression of stress proteins, adhesion molecules, and interleukin-8 in endothelial cells after preservation and reoxygenation. Cryobiology 1999;/38:/106-18.
42. Zimmerman GA, McIntyre TM, Mehra M, Prescott SM. Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. J Cell Biol 1990;/110:/529-40.
43. Tanita T, Song C, Kubo H, Hoshikawa Y, Chida M, Suzuki S, et al. Superoxide anion mediates pulmonary vascular permeability caused by neutrophils in cardiopulmonary bypass. Surg Today 1999;/29:/755-61.
44. Rothenburger M, Trosch F, Markewitz A, Berendes E, Schmid C, Scheld H, et al. Leukocyte activation and phagocytotic activity in cardiac surgery and infection. Cardiovasc Surg 2002;/10:/470-5.
45. Pasnik J, Siniewicz K, Moll JA, Moll J, Baj Z, Sysa A, et al. Effect of cardiopulmonary bypass on neutrophil activity in pediatric open-heart surgery. Arch Immunol Ther Exp 2005;/ 53:/272-7.
46. Hubert K, Krotz-Fahning M, Hock B. Respiratory burst as a biomarker for stress responses. Protoplasma 2006;/229:/221-4.
47. Partrick DA, Moore EE, Fullerton DA, Barnett CCJ, Meldrum DR, Silliman CC. Cardiopulmonary bypass renders patients at risk for multiple organ failure via early neutrophil priming and late neutrophil disability. J Surg Res 1999;/86:/42-9.
48. Pasnik J, Baj Z, Moll JA, Moll J, Moll M, Pokoca L, et al. Effects of cardiopulmonary bypass on the expression of adhesive molecules in children undergoing cardiac surgery due to congenital heart disorders. Kardiol Pol 2004;/60:/ 123-31.
49. Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 2004;/ 61:/461-70.
50. Besse S, Bulteau AL, Boucher F, Riou F, Swynghedauw B, de Leiris J. Antioxidant treatment prevents cardiac protein oxidation after ischemia-reperfusion and improves myocardial function and coronary perfusion in senescent hearts. J Physiol Pharmacol 2006;/57:/541-52.
51. Ryter SW, Kim HP, Hoetzel A, Park JW, Nakahira K, Wang X, et al. Mechanisms of cell death in oxidative stress. Antioxid Redox Signal 2007;/9:/49-89.
52. Kurzelewski M, Czarnowska E, Beresewicz A. Superoxideand nitric oxide-derived species mediate endothelial dysfunction, endothelial glycocalyx disruption, and enhanced neutrophil adhesion in the post-ischemic guinea-pig heart. J Physiol Pharmacol 2005;/56:/163-78.
53. Kohtani T, Abe Y, Sato M, Miyauchi K, Kawachi K. Protective effects of anti-neutrophil antibody against myocardial ischemia/reperfusion injury in rats. Eur Surg Res 2002;/ 34:/313-20.
54. Gando S, Tedo I. Increased neutrophil elastase release in patients with cardiopulmonary arrest: role of elastase inhibitor. Intensive Care Med 1995;/21:/636-40.
55. Farah B, Vuillemenot A, Lecompte T, Bara L, Pasquier C, Jebara V, et al. Myocardial neutrophil sequestration and activation related to the reperfusion on human heart during coronary artery surgery. Cardiovasc Res 1994;/28:/1226-30.
56. Laude K, Richard V, Thuillez C. Coronary endothelial cells: a target of ischemia reperfusion and its treatment? Arch Mal Coeur Vaiss 2004;/97:/250-4.
57. Yanga Q, Yima AP, He GW. The significance of endotheliumderived hyperpolarizing factor in the human circulation. Curr Vasc Pharmacol 2007;/5:/85-92.
58. Nicolls MR, Haskins K, Flores SC. Oxidant stress, immune dysregulation, and vascular function in type I diabetes. Antioxid Redox Signal 2007;/9:/879-89.
59. Lefer AM, Campbell B, Shin YK. Effects of a metalloproteinase that truncates P-selectin glycoprotein ligand on neutrophil- induced cardiac dysfunction in ischemia/reperfusion. J Mol Cell Cardiol 1998;/30:/2561-6.
60. Birnbaum Y, Ye Y, Rosanio S, Tavackoli S, Hu ZY, Schwarz ER, et al. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 2005;/65:/345-55.
61. Cernacek P, Stewart DJ, Monge JC, Rouleau JL. The endothelin system and its role in acute myocardial infarction. Can J Physiol Pharmacol 2003;/81:/598-606.
62. Asano G, Takashi E, Ishiwata T, Onda M, Yokoyama M, Naito Z, et al. Pathogenesis and protection of ischemia and reperfusion injury in myocardium. J Nippon Med Sch 2003;/ 70:/384-92.
63. Lefer AM, Tsao PS, Lefer DJ, Ma XL. Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. FASEB J 1991;/5:/2029-34.
64. Saini HK, Machackova J, Dhalla NS. Role of reactive oxygen species in ischemic preconditioning of subcellular organelles in the heart. Antioxid Redox Signal 2004;/6:/393-404.
65. Lefer AM, Lefer DJ. Is microcirculation important in reperfusion in man. Dial Cardiovasc Med 1998;/65:/1751-62.
66. Turkoz R, Yorukoglu K, Akcay A, Yilik L, Baltalarli A, Karahan N, et al. The effect of pentoxifylline on the lung during cardiopulmonary bypass. Eur J Cardiothorac Surg 1996;/10:/339-46.
67. Hill GE, Pohorecki R, Alonso A, Rennard SI, Robbins RA. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg 1996;/83:/696-700.
68. Karaca P, Konuralp C, Enc Y, Suzer A, Sokullu O, Avoglu U, et al. Cardioprotective effect of aprotinin on myocardial ischemia/reperfusion injury during cardiopulmonary bypass. Circ J 2006;/70:/1432-6. (Pubitemid 44672899)
69. Oostingh GJ, Pozgajova M, Ludwig RJ, Krahn T, Boehncke WH, Nieswandt B, et al. Diminished thrombus formation and alleviation of myocardial infarction and reperfusion injury through antibody- or small-molecule-mediated inhibition of selectin-dependent platelet functions. Haematologica 2007;/ 92:/502-12.
70. Lefer DJ, Flynn DM, Buda AJ. Effects of a monoclonal antibody directed against P-selectin after myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol 1996;/270:/ H88-98.
71. Murry CE, Jenings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;/75:/1124-36.
72. Youker KA, Beirne J, Lee J, Michael LH, Smith CW, Entman ML. Time dependent loss of Mac-1 from infiltrating neutrophils in the reperfused myocardium. J Immunol 2000;/164:/ 2752-8.
73. Fukushima S, Coppen SR, Varela-Carver A, Yamahara K, Sarathchandra P, Smolenski RT, et al. A novel strategy for myocardial protection by combined antibody therapy inhibiting both P-selectin and intercellular adhesion molecule-1 via retrograde intracoronary route. Circulation 2006;114(Suppl): I251-6.
74. Simpson PJ, Todd RF, Fantone JC, Mickelson JK, Griffin JD, Lucchesi BR. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti- CD11b) that inhibits leukocyte adhesion. J Clin Invest 1988;/ 81:/624-9.
75. Simpson PJ, Todd RF, Mickelson JK, Fantone JC, Gallagher KP, Lee KA, et al. Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function. Circulation 1990;/81:/226-37.
76. Garner JR, Stroud RE, Finklea L, Ikonomidis JS, Dorman BH, Spinale FG. The effects of leukocyte reduction on matrix metalloproteinase release in cardiopulmonary bypass. J Extra Corpor Technol 2004;/36:/185-90.
77. Ilmakunnas M, Pesonen EJ, Ahonen J, Ramo J, Siitonen S, Repo H. Activation of neutrophils and monocytes by a leukocyte-depleting filter used throughout cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005;/130:/952-3.
78. Johnell M, Elgue G, Thelin S, Larsson R, Siegbahn A. Cell adhesion and tissue factor upregulation in oxygenators used during coronary artery bypass grafting are modified by the Corline Heparin Surface. Scand Cardiovasc J 2002;/36:/351-7.
79. Ueyama K, Nishimura K, Nishina T, Nakamura T, Ikeda T, Komeda M. PMEA coating of pump circuit and oxygenator may attenuate the early systemic inflammatory response in cardiopulmonary bypass surgery. ASAIO J 2004;/50:/369-72.
80. Duda M, Czarnowska E, Kurzelewski M, Konior A, Beresewicz A. Ischemic preconditioning prevents endothelial dysfunction, P-selectin expression, and neutrophil adhesion by preventing endothelin and O2-generation in the postischemic guinea-pig heart. Physiol Pharmacol 2006;/57:/ 553-69.
81. Teoh LK, Grant R, Hulf JA, Pugsley WB, Yellon DM. The effect of preconditioning (ischemic and pharmacological) on myocardial necrosis following coronary artery bypass graft surgery. Cardiovasc Res 2002;/53:/175-80.
82. Vinten-Johansen J, Thourani VH, Ronson RS, Jordan JE, Zhao ZQ, Nakamura M, et al. Broad-spectrum cardioprotection with adenosine. Ann Thorac Surg 1999;/68:/1942-8.
83. +T lymphocytes. Circulation 2006;/114:/2056-64.
84. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999;/34:/1711-20.
85. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW, AMISTAD-II Investigators. A randomized, doubleblinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45: 1775-80.